Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Immupharma files international patent application for P140 precision medicine
Immupharma has filed a PCT application for its P140 approach to identify and treat patients with the so-called type-M immune profile. The application builds on a UK patent (priority Aug/Sep 2025) and includes additional experimental data generated during the 12-month priority period. The international phase includes search and publication and enables the pursuit of national/regional patent rights in selected markets. The company names P140 as a central value driver and aims to conclude a commercial agreement in 2026. » Altro su de.investing.com
ImmuPharma selects Kymos Group as CRO for Kapiglucagon bioanalysis
ImmuPharma has chosen Kymos Deutschland/Prolytic through a competitive tender as the bioanalytical contract research partner for the Kapiglucagon program. Kymos will develop and validate regulated bioanalytical methods and analyse samples from nonclinical and phase 1 studies. Kapiglucagon is a glucagon prodrug intended for type 1 diabetes applications, aiming to improve solubility and formulation stability for dual-hormone artificial pancreas systems. The program is supported by recently awarded funding; Thermo Fisher is the CMC partner and Bachem is supplying the API, and a US regulatory pathway via 505(b)(2) is being explored. » Altro su de.investing.com
ImmuPharma starts IND preparations for diabetes prodrug Kapiglucagon
ImmuPharma has initiated IND‑preparatory activities for Kapiglucagon, a glucagon prodrug for treating type 1 diabetes, and has engaged tranScrip Limited to prepare a regulatory strategy and a pre‑IND briefing for the FDA. The company is considering a 505(b)(2) approval pathway in the US, which could allow use of existing data on native glucagon. Kapiglucagon aims to address issues with native glucagon by providing improved solubility and formulation stability and could also be used in artificial pancreas systems. After the pre‑IND meeting, ImmuPharma plans to submit an IND and start first human studies; the program is supported by a recently approved financing initiative. » Altro su de.investing.com
ImmuPharma launches retail offer to raise £1.5 million
ImmuPharma is offering private investors, via Winterflood Retail Access, 25 million new ordinary shares at 6.0 pence each to raise up to £1.5 million. A separate placing of around £7.5 million is running in parallel at the same price. The subscription period is expected to end on Friday, with a minimum subscription of £100; results are scheduled for 23 March 2026, and the issue is subject to shareholder approval and admission to trading on AIM. » Altro su de.investing.com
ImmuPharma delays P140 partnership completion to 2026
ImmuPharma has postponed the planned closing of a partnership for its P140 autoimmune platform from the end of 2025 to 2026. The company is in talks with several potential partners, including some of the world’s ten largest pharmaceutical firms, and multiple confidentiality agreements have been signed. ImmuPharma says it is seeking the most suitable partner with a focus on long-term value creation; liquidity runway has been extended into the fourth quarter of 2026 through tax credits, option exercises and around £2m from a sharing agreement, and no further capital measures are planned. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | -576,92 | 98,26% |
| Utile netto | -5,46 Mln | 409,81% |
| EBITDA | -1,24 Mln | 77,13% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 21,09 Mln € |
Numero di azioni | 623,91 Mln |
Massimo/minimo a 52 settimane | 0,13 € - 0,03 € |
| Dividendi | No |
Beta | 3,02 |
Rapporto P/E | -2,26 |
Rapporto PEG | 0,02 |
Rapporto P/B | 8,66 |
Rapporto P/S | 0,00 |
Profilo aziendale
ImmuPharma plc, una società biofarmaceutica, scopre e sviluppa terapie a base peptidica. Le sue terapie a base peptidica sono utilizzate nelle aree terapeutiche dell'autoimmunità e dell'infiammazione, e degli anti-infettivi. Il candidato prodotto principale della società è Lupuzor, un immunomodulatore dell'autofagia, che si trova in fase III di sperimentazione clinica per il trattamento del lupus, una malattia infiammatoria cronica autoimmune. Tra gli altri candidati prodotto figurano BioAMB, un farmaco a base peptidica per il trattamento delle formulazioni di Amphotericin-B, un'infezione fungina causata dalla famiglia di funghi Aspergillus; e BioCin, un farmaco antibatterico a base peptidica utilizzato nei casi di elevata necessità medica e come ultima linea di difesa. La società ha un accordo di collaborazione con il Centre National de la Recherche Scientifique per lo sviluppo di una piattaforma tecnologica peptidica per il trattamento del diabete con agonisti del peptide-1 simile al glucagone, nonché per lo sviluppo di peptidi come antagonisti del glucagone per il trattamento del diabete di tipo I e di tipo II; e un accordo di licenza e sviluppo con Avion Pharmaceuticals LLC. ImmuPharma plc è stata fondata nel 1999 e ha sede a Londra, nel Regno Unito.
| Nome | ImmuPharma |
| CEO | Timothy Paul McCarthy |
| Sede centrale | London,
gl Regno Unito |
| Sito web | |
| Quotazione in borsa | 28/10/2003 |
| Dipendenti | 7 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
London Stock Exchange | IMM.L |
Frankfurt | 25I.F |
London | IMM.L |
München | 25I.MU |